在患有新血管年龄相关黄斑退行症的患者中,brolucizumab后的三年视觉结果
Yume Kobayashi1, Maiko Maruyama-Inoue2, Tatsuya Inoue1
1Department of Ophthalmology, Yokohama City University Medical Center, 57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.
BMC ophthalmology
|April 14, 2025
概括
治疗和延长 (TAE) 治疗新血管年龄相关黄斑退行症患者的静脉内勃鲁西祖马布治疗方案,与预先治疗 (PRN) 方法相比,显示出更好的3年视力敏度结果. 基线视力敏度和中央骨厚度也影响了结果.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理疗法 药理疗法 药理疗法
背景情况:
- 神经血管与年龄相关的黄斑变性 (nAMD) 是导致视力丧失的主要原因.
- 静脉内勃鲁西祖马布是nAMD的治疗选择,但其长期疗效需要进一步研究.
- 了解影响视力敏度 (VA) 结果的因素对于优化患者管理至关重要.
研究的目的:
- 评估在患有nAMD的患者中,静脉内布罗卢齐祖马布治疗3年后的结果.
- 为了确定影响视敏度 (VA) 在三年内变化的因素.
- 为了比较不同治疗方案 (pro re nata vs. 治疗和扩展) 对VA的疗效.
主要方法:
- 一组患有nAMD的患者接受了初始的每月一次布罗卢齐祖马布注射,然后进行12个月的预先注射 (PRN) 或治疗和延长 (TAE) 方案.
- 最好的视力敏度 (BCVA) 在基线和治疗后4,12和36个月被测量.
- 进行了统计分析,以确定36个月后与VA改善和形态特征相关的因素.
主要成果:
- 与基线相比,TAE组在12个月和36个月后显示出BCVA的统计学上显著改善.
- 与基线相比,PRN组在任何随访点都没有显示出明显的BCVA改善.
- 基线BCVA,中央骨厚度 (CFT) 和TAE疗法是VA改善的显著预测因素;36个月后下液 (SRF) 的存在与更好的VA相关.
结论:
- 治疗和延长 (TAE) 方案使得nAMD患者在3年内获得优异的视觉结果,这些患者接受了brolucizumab治疗.
- 在维护阶段,如果中心骨厚度 (CFT) 变化最小,则可以容忍剩余下液 (SRF).
- 与PRN相比,TAE疗法是维持和改善nAMD视力的更有效策略.
关键词:
与年龄有关的黄斑变性.抗血管内皮生长因子 抗血管内皮生长因子布罗卢西祖马布 (brolucizumab) 是一种药物.聚合性冠状血管病变 (Polypoidal choroidal vasculopathy) 是一种多重的血管病变.下视网膜下液体是什么意思更多相关视频
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
976
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
182
相关概念视频
Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
